Enochian Biosciences, Inc., a biotechnology firm in the pre-clinical stage, has been actively involved in developing biological and pharmaceutical products primarily aimed at combating Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), and cancer. The company's project pipeline enfolds ENOB-HV-01, which is an autologous HIV curative treatment, ENOB-HV-12 (a therapeutic HIV vaccine), and ENOB-HB-01 (a gene therapy curative treatment for HBV). Furthermore, the firm is pioneering ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors, ENOB-DC-12-XX (an allogeneic dendritic cell therapeutic vaccine for other solid tumors), and ENOB-HV-21 - an experimental therapy for treating HIV by utilizing allogeneic natural killer and gamma delta T-cells. Enochian Biosciences, Inc. has entered into strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company, which was incorporated in 2017, is headquartered in Los Angeles, California, and is making significant progress in its mission to develop effective treatments for some of humanity's most pressing health issues.
Enochian Biosciences, Inc.'s ticker is ENOB
The company's shares trade on the NASDAQ stock exchange
They are based in Los Angeles, California
There are 1-10 employees working at Enochian Biosciences, Inc.
It is https://www.enochianbio.com/
Enochian Biosciences, Inc. is in the Healthcare sector
Enochian Biosciences, Inc. is in the Biotechnology industry
The following five companies are Enochian Biosciences, Inc.'s industry peers: